BR112012011518B8 - Compostos, composição farmacêutica, kit e usos de um composto - Google Patents
Compostos, composição farmacêutica, kit e usos de um compostoInfo
- Publication number
- BR112012011518B8 BR112012011518B8 BR112012011518A BR112012011518A BR112012011518B8 BR 112012011518 B8 BR112012011518 B8 BR 112012011518B8 BR 112012011518 A BR112012011518 A BR 112012011518A BR 112012011518 A BR112012011518 A BR 112012011518A BR 112012011518 B8 BR112012011518 B8 BR 112012011518B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- kit
- pharmaceutical composition
- methyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 4
- -1 2-((2-(2 Chemical class 0.000 abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26226309P | 2009-11-18 | 2009-11-18 | |
| US61/262263 | 2009-11-18 | ||
| PCT/SE2010/051269 WO2011062550A1 (en) | 2009-11-18 | 2010-11-17 | Benzoimidazole compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012011518A2 BR112012011518A2 (pt) | 2016-06-28 |
| BR112012011518B1 BR112012011518B1 (pt) | 2020-03-10 |
| BR112012011518B8 true BR112012011518B8 (pt) | 2023-01-10 |
Family
ID=44059844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012011518A BR112012011518B8 (pt) | 2009-11-18 | 2010-11-17 | Compostos, composição farmacêutica, kit e usos de um composto |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8530467B2 (https=) |
| EP (1) | EP2501697B1 (https=) |
| JP (1) | JP5657018B2 (https=) |
| KR (1) | KR20120113709A (https=) |
| CN (1) | CN102741245B (https=) |
| AR (1) | AR079050A1 (https=) |
| AU (1) | AU2010322478B2 (https=) |
| BR (1) | BR112012011518B8 (https=) |
| CA (1) | CA2777746C (https=) |
| ES (1) | ES2442797T3 (https=) |
| IN (1) | IN2012DN03391A (https=) |
| MX (1) | MX2012005329A (https=) |
| RU (1) | RU2542582C2 (https=) |
| TW (1) | TW201121957A (https=) |
| UY (1) | UY33037A (https=) |
| WO (1) | WO2011062550A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158117A1 (en) * | 2011-05-17 | 2012-11-22 | Astrazeneca Ab | Combination therapies for treating pain |
| US9598409B2 (en) * | 2013-01-31 | 2017-03-21 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| CN105992761A (zh) * | 2013-12-20 | 2016-10-05 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法 |
| US10195198B2 (en) | 2014-07-03 | 2019-02-05 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| WO2020135771A1 (zh) * | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| JP2023513373A (ja) * | 2020-02-14 | 2023-03-30 | べルス・ヘルス・コフ・インコーポレーテッド | Ｐ２ｘ３修飾薬 |
| EP4198034A4 (en) * | 2020-08-13 | 2024-01-17 | Tuojie Biotech (Shanghai) Co., Ltd. | BENZIMIDAZOLE DERIVATIVES, PRODUCTION PROCESS THEREOF AND MEDICAL USE THEREOF |
| TW202227458A (zh) * | 2020-12-04 | 2022-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含有稠合三環的化合物及其醫藥用途 |
| CN114478508A (zh) * | 2021-12-31 | 2022-05-13 | 淮北师范大学 | 一种苯并咪唑化合物的结晶形式 |
| WO2023151658A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 一种p2x3受体拮抗剂的可药用盐及其制备方法 |
| WO2023151660A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 一种p2x3受体拮抗剂的结晶形式及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6026A (en) * | 1849-01-09 | Cast-iron car-wheel | ||
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| CN100415723C (zh) * | 2000-01-17 | 2008-09-03 | 帝人株式会社 | 苯并咪唑衍生物 |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| MX2007003105A (es) * | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| CN101674827A (zh) * | 2007-03-02 | 2010-03-17 | 先灵公司 | 苯并咪唑衍生物及其使用方法 |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| CA2703909A1 (en) * | 2007-10-31 | 2009-05-07 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
-
2010
- 2010-11-17 BR BR112012011518A patent/BR112012011518B8/pt active IP Right Grant
- 2010-11-17 CA CA2777746A patent/CA2777746C/en active Active
- 2010-11-17 MX MX2012005329A patent/MX2012005329A/es active IP Right Grant
- 2010-11-17 IN IN3391DEN2012 patent/IN2012DN03391A/en unknown
- 2010-11-17 WO PCT/SE2010/051269 patent/WO2011062550A1/en not_active Ceased
- 2010-11-17 EP EP10831876.7A patent/EP2501697B1/en active Active
- 2010-11-17 KR KR1020127012726A patent/KR20120113709A/ko not_active Withdrawn
- 2010-11-17 AU AU2010322478A patent/AU2010322478B2/en active Active
- 2010-11-17 CN CN201080061596.6A patent/CN102741245B/zh active Active
- 2010-11-17 TW TW099139607A patent/TW201121957A/zh unknown
- 2010-11-17 JP JP2012539853A patent/JP5657018B2/ja active Active
- 2010-11-17 ES ES10831876.7T patent/ES2442797T3/es active Active
- 2010-11-17 AR ARP100104240A patent/AR079050A1/es unknown
- 2010-11-17 RU RU2012124268/04A patent/RU2542582C2/ru active
- 2010-11-18 UY UY0001033037A patent/UY33037A/es not_active Application Discontinuation
-
2012
- 2012-05-16 US US13/472,825 patent/US8530467B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2442797T3 (es) | 2014-02-13 |
| EP2501697A4 (en) | 2013-04-24 |
| EP2501697A1 (en) | 2012-09-26 |
| AR079050A1 (es) | 2011-12-21 |
| UY33037A (es) | 2011-06-30 |
| CN102741245B (zh) | 2014-11-05 |
| EP2501697B1 (en) | 2013-10-23 |
| RU2012124268A (ru) | 2013-12-27 |
| AU2010322478B2 (en) | 2013-11-14 |
| CA2777746C (en) | 2019-05-14 |
| RU2542582C2 (ru) | 2015-02-20 |
| US20120289504A1 (en) | 2012-11-15 |
| BR112012011518B1 (pt) | 2020-03-10 |
| CN102741245A (zh) | 2012-10-17 |
| MX2012005329A (es) | 2012-05-29 |
| IN2012DN03391A (https=) | 2015-10-23 |
| WO2011062550A1 (en) | 2011-05-26 |
| JP5657018B2 (ja) | 2015-01-21 |
| BR112012011518A2 (pt) | 2016-06-28 |
| US8530467B2 (en) | 2013-09-10 |
| KR20120113709A (ko) | 2012-10-15 |
| AU2010322478A1 (en) | 2012-05-31 |
| CA2777746A1 (en) | 2011-05-26 |
| JP2013511517A (ja) | 2013-04-04 |
| TW201121957A (en) | 2011-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012011518B8 (pt) | Compostos, composição farmacêutica, kit e usos de um composto | |
| BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
| BR112013006953A2 (pt) | composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença | |
| BR112013008211A8 (pt) | Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende | |
| BRPI0821994B8 (pt) | composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| CL2007003870A1 (es) | Uso de compuestos derivados de acido 1-(3-piridinil)pirazol-4-il-aceticos; dichos compuestos derivados o una de sus sales; procedimiento de preparacion de dichos compuestos; agente herbicida o regulador del crecimiento de las plantas; y procedimiento | |
| BR112014006297A2 (pt) | inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica | |
| BRPI0607796A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica | |
| BR112013006030A2 (pt) | composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica | |
| BRPI0806365B8 (pt) | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica | |
| CY1113594T1 (el) | Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης | |
| BRPI0818533B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
| BRPI0607402A2 (pt) | uso de inibidores de pde7 para o tratamento de dor neuropática | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| BR112012021652A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| BR112012021659A2 (pt) | composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças. | |
| CL2008001367A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana. | |
| BRPI0510043A (pt) | método de tratamento de dor neuropática usando antagonista de receptor crth2 | |
| BR112012022064A2 (pt) | tratamento de artrite lúpica usando laquinimod | |
| BR112012009496A2 (pt) | composição farmacêutica, e, método para tratar diabetes tipo 2 | |
| BRPI0914371A2 (pt) | "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação" | |
| BR112013024368A8 (pt) | Combinações de composto ativo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: NEOMED INSTITUTE (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: BELLUS HEALTH COUGH INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: BELLUS HEALTH INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: 14245563 CANADA INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED (GB) |